DK3538134T3 - Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse - Google Patents
Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse Download PDFInfo
- Publication number
- DK3538134T3 DK3538134T3 DK17801644.0T DK17801644T DK3538134T3 DK 3538134 T3 DK3538134 T3 DK 3538134T3 DK 17801644 T DK17801644 T DK 17801644T DK 3538134 T3 DK3538134 T3 DK 3538134T3
- Authority
- DK
- Denmark
- Prior art keywords
- prophylaxation
- trunked
- treatment
- blood coagulation
- von willebrand
- Prior art date
Links
- 208000015294 blood coagulation disease Diseases 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 108010047303 von Willebrand Factor Proteins 0.000 title 1
- 102100036537 von Willebrand factor Human genes 0.000 title 1
- 229960001134 von willebrand factor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16198497 | 2016-11-11 | ||
| PCT/EP2017/078840 WO2018087271A1 (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3538134T3 true DK3538134T3 (da) | 2022-02-07 |
Family
ID=57389201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17801644.0T DK3538134T3 (da) | 2016-11-11 | 2017-11-10 | Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11890327B2 (enExample) |
| EP (1) | EP3538134B1 (enExample) |
| JP (1) | JP2020504082A (enExample) |
| KR (1) | KR20190073576A (enExample) |
| CN (1) | CN110381986B (enExample) |
| AU (1) | AU2017358865A1 (enExample) |
| CA (1) | CA3043397A1 (enExample) |
| DK (1) | DK3538134T3 (enExample) |
| ES (1) | ES2908008T3 (enExample) |
| SG (2) | SG10201912768YA (enExample) |
| TW (1) | TW201828974A (enExample) |
| WO (1) | WO2018087271A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| KR20220029733A (ko) | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
| EP4058049A1 (en) | 2019-11-11 | 2022-09-21 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| KR102647642B1 (ko) * | 2021-05-04 | 2024-03-15 | (주)케어젠 | 혈액 응고 활성을 갖는 펩타이드와 이의 용도 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| EP1621206A1 (en) | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| CA2252896C (en) | 1996-04-24 | 2009-03-10 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| EP1351986A2 (en) | 2001-01-12 | 2003-10-15 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| EP2110385A1 (en) | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| WO2003093313A2 (en) | 2002-04-29 | 2003-11-13 | Baxter International Inc. | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| WO2004075923A2 (en) | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| KR101468345B1 (ko) | 2004-11-12 | 2014-12-03 | 바이엘 헬스케어 엘엘씨 | Ｆｖｉｉｉ의 부위 지향 변형 |
| BRPI0519562A2 (pt) | 2004-12-27 | 2009-01-27 | Baxter Int | construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea |
| KR20080007226A (ko) | 2005-04-14 | 2008-01-17 | 체에스엘 베링 게엠베하 | 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체 |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| KR20080108147A (ko) | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
| DK3896090T3 (da) | 2006-06-14 | 2022-03-21 | Csl Behring Gmbh | Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor |
| CA2673459C (en) | 2006-12-22 | 2016-09-13 | Stefan Schulte | Modified coagulation factors with prolonged in vivo half-life |
| AU2008261261B2 (en) | 2007-06-13 | 2013-06-27 | Csl Behring Gmbh | Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
| DK2865760T3 (en) | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
| KR101808751B1 (ko) | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| EP2804623B1 (en) | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
| WO2013083858A1 (en) | 2012-04-24 | 2013-06-13 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| WO2013160005A1 (en) | 2012-04-24 | 2013-10-31 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
| CN110054699A (zh) | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| US20160207977A1 (en) * | 2013-06-12 | 2016-07-21 | Novo Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| CA2949323A1 (en) | 2014-06-06 | 2015-12-10 | Octapharma Ag | Preparation comprising factor viii and von willebrand factor peptides |
| BR112016030950A2 (pt) | 2014-07-02 | 2018-03-27 | Csl Ltd | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. |
| US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
-
2017
- 2017-11-10 TW TW106139051A patent/TW201828974A/zh unknown
- 2017-11-10 SG SG10201912768YA patent/SG10201912768YA/en unknown
- 2017-11-10 ES ES17801644T patent/ES2908008T3/es active Active
- 2017-11-10 US US16/349,002 patent/US11890327B2/en active Active
- 2017-11-10 CN CN201780069945.0A patent/CN110381986B/zh active Active
- 2017-11-10 EP EP17801644.0A patent/EP3538134B1/en active Active
- 2017-11-10 CA CA3043397A patent/CA3043397A1/en not_active Abandoned
- 2017-11-10 SG SG11201903954WA patent/SG11201903954WA/en unknown
- 2017-11-10 AU AU2017358865A patent/AU2017358865A1/en not_active Abandoned
- 2017-11-10 JP JP2019524345A patent/JP2020504082A/ja active Pending
- 2017-11-10 KR KR1020197016644A patent/KR20190073576A/ko not_active Withdrawn
- 2017-11-10 DK DK17801644.0T patent/DK3538134T3/da active
- 2017-11-10 WO PCT/EP2017/078840 patent/WO2018087271A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3538134A1 (en) | 2019-09-18 |
| US11890327B2 (en) | 2024-02-06 |
| EP3538134B1 (en) | 2021-12-29 |
| CA3043397A1 (en) | 2018-05-17 |
| JP2020504082A (ja) | 2020-02-06 |
| ES2908008T3 (es) | 2022-04-27 |
| AU2017358865A1 (en) | 2019-05-09 |
| WO2018087271A1 (en) | 2018-05-17 |
| CN110381986A (zh) | 2019-10-25 |
| SG11201903954WA (en) | 2019-05-30 |
| SG10201912768YA (en) | 2020-02-27 |
| US20210268071A1 (en) | 2021-09-02 |
| KR20190073576A (ko) | 2019-06-26 |
| TW201828974A (zh) | 2018-08-16 |
| CN110381986B (zh) | 2023-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271956A (en) | Blood pump | |
| EP3731850A4 (en) | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES | |
| EP3538078A4 (en) | FORMULATIONS FOR EFFICIENT CANNABINOID DELIVERY | |
| EP3453414C0 (en) | ADJUSTING INSULIN DOSES | |
| DK3912673T3 (da) | Blodpumpe | |
| MA46284A (fr) | Canule cardiaque | |
| DK3413948T3 (da) | Blodpumpesystem | |
| DE112017001906A5 (de) | Kanülenanordnung und Blutpumpenanordnung sowie deren Verwendung | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| EP3595681A4 (en) | TRANSPLANT CELL-BASED IMMUNOTHERAPY FOR LONG-PERIOD ADMINISTRATION OF THERAPEUTIC PROTEIN | |
| EP3536032A4 (en) | INTER-RAT CONFIGURATION COORDINATION | |
| DK4212152T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af kronisk systolisk hjertesvigt | |
| DK3297656T3 (da) | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili | |
| DE112017004905A5 (de) | Blutpumpe | |
| SG10201912768YA (en) | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | |
| EP3419498C0 (en) | MEDICAL GAS DISTRIBUTION SYSTEM | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3585808T3 (da) | Modificerede serpiner til behandlingen af bradykinin formidlet sygdom | |
| IL261968A (en) | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use | |
| EP3528860C0 (en) | CELL-ASSOCIATED SCAFFOLDS FOR AGENT DELIVERY | |
| EP4046609C0 (en) | EXTENDED PHARMACOLOGICAL RELEASE OPHTHALMIC FORMULATION AND ITS USES | |
| DK3818078T3 (da) | Fremgangsmåder til fremstilling af rekombinante proteiner | |
| DE112018006114A5 (de) | Kanüle, kanülensystem und blutpumpensystem | |
| DK3618845T3 (da) | Peptider til behandling af diabetes |